Provided by Tiger Trade Technology Pte. Ltd.

Edgewise Therapeutics, Inc.

45.25
+0.53001.19%
Volume:572.10K
Turnover:25.81M
Market Cap:4.91B
PE:-24.46
High:46.31
Open:45.22
Low:44.68
Close:44.72
52wk High:48.40
52wk Low:13.69
Shares:108.60M
Float Shares:88.17M
Volume Ratio:0.58
T/O Rate:0.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8502
EPS(LYR):-1.6302
ROE:-38.03%
ROA:-25.03%
PB:10.97
PE(LYR):-27.76

Loading ...

Edgewise Says Phase 2 Cirrus-HCM Trial Shows Positive Top-Line Data for EDG-7500 in Hypertrophic Cardiomyopathy

Reuters
·
Aug 24

Egetis Bolsters Finances and IP as Emcitate Nears Key FDA Decision

TIPRANKS
·
Aug 21

Edgewise Therapeutics Price Target Raised to $60.00/Share from $53.00 by JP Morgan

Dow Jones
·
Aug 21

Edgewise Therapeutics price target raised to $60 from $53 at JPMorgan

TIPRANKS
·
Aug 20

Edgewise Therapeutics (EWTX) Is Up 6.6% After Wider Q2 Losses Highlight Rising Spend - Has The Bull Case Changed?

Simply Wall St.
·
Aug 20

Edgewise Therapeutics (EWTX) Reports Wider Losses On A Valuation That Still Looks Rich

Simply Wall St.
·
Aug 17

Edgewise Therapeutics CMO Joanne M. Donovan Disposes of USD 411,192 in Common Shares

Reuters
·
Aug 15

Edgewise Therapeutics is Maintained at Neutral by Goldman Sachs

Dow Jones
·
Aug 12

Edgewise Therapeutics price target raised to $36 from $32 at Goldman Sachs

TIPRANKS
·
Aug 11

Wedbush Adjusts Pt on Edgewise Therapeutics to $53 From $52, Maintains Outperform Rating

MT Newswires Live
·
Aug 07

Edgewise Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Edgewise Therapeutics Q2 EPS $(0.53) Misses $(0.47) Estimate

Benzinga Earnings
·
Aug 06

Edgewise Therapeutics Q2 Operating Income USD -61.943 Million

Reuters
·
Aug 06

Edgewise Net Loss Widens 58.74% to $57.33 Million in Q2 FY26

Reuters
·
Aug 06

Edgewise Therapeutics Q2 Operating Expenses USD 61.943 Million

THOMSON REUTERS
·
Aug 06

Edgewise Therapeutics Q2 Basic EPS USD -0.53

THOMSON REUTERS
·
Aug 06

Press Release: Edgewise Therapeutics Reports Second Quarter 2026 Financial Results

Dow Jones
·
Aug 06

Edgewise’s EDG-15400 Phase 1 Milestone: What It Means for EWTX Investors

TIPRANKS
·
Aug 06

Edgewise Therapeutics is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
Jul 20

Edgewise Therapeutics price target raised to $55 from $45 at Evercore ISI

TIPRANKS
·
Jul 20